Billy Dunn, FDA’s top neuroscience official to depart agency

The US Food and Drug Administration’s (FDA) top neuroscience official, Billy Dunn, who oversaw the controversial approval of Biogen’s Alzheimer’s disease drug Aduhelm (aducanumab-avwa), is leaving the agency after an 18-year tenure.